Dr in charge of CSCI's avenanthramide trial welcomes new era"The FDA's approval of colchicine confirms that we are entering a new era of patient care, now targeting inflammation as an underlying cause of atherosclerotic coronary artery disease," said Dr. Jean-Claude Tardif.